Integrated Assessment for Cardiac liabilities

Product Details

In 2020, ICH E14/S7B cardiac safety regulations was updated: The role of in vitro assays was expanded and the “Double-Negative” scenario was suggested. Therefore, we develop a systematic strategy to assess preclinical cardiac safety: CardiacOneTM

Our CardiacOneTM will assess cardiotoxicity in three aspects: electrophysiological abnormalities, contractile dysfunction, and structural toxicity

Cardiac pharmacological study platform

Multiple cardiac ion channel patch clamp or automated patch clamp (Beyond CiPA related channels)

Cardiac pharmacological study using acutely isolated cardiomyocytes (from human, monkey, canine, rabbit, Guinea pig, rats or mice) or iPSCs-derived cardiomyocytes

Langendorff perfusion of isolated heart and in vivo ECG recording

Cardiac action potential assays of Purkinje fibers and papillary muscle